Zero-Order Kinetics in Pharmacokinetics
Zero-order kinetics describes drug elimination that occurs at a constant rate, independent of the drug concentration in the body—meaning the same absolute amount of drug is eliminated per unit time regardless of how much drug is present.
Core Concept
In zero-order kinetics, the elimination rate remains constant and does not change with drug concentration 1. This contrasts fundamentally with first-order kinetics, where elimination rate is proportional to the drug concentration present 2.
Mathematical Distinction
- Zero-order: Elimination proceeds at a fixed rate (e.g., 10 mg/hour), regardless of whether 100 mg or 20 mg remains in the body
- First-order: Elimination rate changes proportionally with concentration (e.g., 10% per hour of whatever amount is present)
When Zero-Order Kinetics Occurs
Zero-order kinetics emerges when metabolic or elimination pathways become saturated 3. This happens when:
- Drug concentrations exceed the capacity of enzymes or transporters
- The Michaelis constant (Km) is exceeded
- Binding sites on metabolizing enzymes become fully occupied
The evidence indicates that zero-order kinetics represents a special case of saturable processes described by the law of mass action 3. When drug concentrations are high enough to saturate elimination mechanisms, the system can no longer increase its elimination rate proportionally—it maxes out at a constant rate.
Clinical Examples
Classic Example: Ethanol
Alcohol is the prototypical zero-order drug, eliminated at approximately 7-10 g/hour regardless of blood alcohol concentration (once above minimal levels) 3.
Other Drugs Exhibiting Zero-Order Kinetics:
- Phenytoin: At therapeutic concentrations, hepatic enzymes become saturated 3
- Aspirin: At high doses, metabolic pathways saturate
- Mibefradil: Demonstrates zero-order kinetics at repeated doses of 50-100 mg due to decreased hepatic extraction 4
Critical Clinical Implications
1. Unpredictable Drug Accumulation
When elimination pathways saturate, small dose increases can cause disproportionately large increases in drug concentration 3. This creates significant toxicity risk.
2. Loss of Proportionality
Doubling the dose does NOT double the steady-state concentration—it may increase it 5-fold or 10-fold 3.
3. Prolonged Elimination
Once pathways are saturated, it takes much longer to eliminate the drug. The drug doesn't follow the predictable exponential decay of first-order kinetics 1.
4. Narrow Therapeutic Windows
Drugs exhibiting zero-order kinetics often have small therapeutic windows, making dosing adjustments particularly hazardous 5.
Common Pitfalls
Assuming linear dose-response relationships: Clinicians accustomed to first-order kinetics may dangerously assume that a 20% dose increase will produce a 20% increase in drug levels. With zero-order kinetics, this assumption can lead to severe toxicity 3.
Ignoring saturation at higher doses: Many drugs follow first-order kinetics at low concentrations but switch to zero-order kinetics at higher therapeutic or toxic concentrations 3, 4. The transition point varies by drug and patient factors.
Relationship to First-Order Kinetics
The evidence clarifies that zero-order and first-order kinetics are not separate phenomena but rather extreme ends of the same saturable process described by Michaelis-Menten kinetics 3:
- When drug concentration << Km: First-order kinetics predominate
- When drug concentration >> Km: Zero-order kinetics predominate
- At intermediate concentrations: Mixed or Michaelis-Menten kinetics apply
Practical Monitoring Considerations
For drugs with zero-order kinetics:
- Therapeutic drug monitoring is essential 3
- Small dose adjustments (10-15% maximum) are safer than large changes
- Allow adequate time (often weeks) to reach new steady state after dose changes
- Watch for early signs of toxicity, as accumulation can be rapid and nonlinear
The clinical relevance extends beyond simple pharmacokinetics—understanding zero-order kinetics is foundational for safe prescribing of drugs with saturable elimination pathways and for recognizing when standard dosing assumptions no longer apply 6.